贝伐珠单抗致严重肠穿孔  

Severe intestinal perforation due to bevacizumab

作　　者：徐敬朴[1] 孔薇[2] 代文婷[2] 郑丽亚[1] 傅昌芳[2] 

机构地区：[1]河北医科大学第二医院药学部,石家庄050000 [2]安徽省立医院药剂科

出　　处：《药物不良反应杂志》2015年第4期310-311,共2页Adverse Drug Reactions Journal

摘　　要：1例65岁女性患者因结肠癌伴肝转移行贝伐珠单抗（0．386g，第1天）联合奥沙利铂（150mg，第1天）、卡培他滨（1g，2次／d，第1～14天）方案化疗。首次化疗后第23天，患者出现中上腹部疼痛，腹部X线片和CT检查诊断为消化道穿孔、弥漫性腹膜炎。急诊行剖腹探查术，术中见升结肠距回盲部约5cm处穿孔，大小约5om×2cm，行升结肠造瘘＋末端回肠造瘘术。术后待患者病情稳定后改用奥沙利铂联合卡培他滨方案继续化疗。A 65-year-old female patient was given treatment scheme of bevacizumab （0. 386 g, the first day）, oxaliplatin （150 mg, the first day） and capecitabine （1 g, twice daily, the first day to the 14th day） for colon cancer with liver metastasis. Twenty-three days after administration, the patient developed upper abdominal pain. She was diagnosed of gastrointestinal perforation and diffuse peritonitis by abdominal X-ray and CT scan. Emergency exploratory laparotomy was performed and a perforation with a size about 5 cm × 2 cm was found at the location of ascending colon 5 em away from ileocecus. Then an ascending colon and terminal ileum fistula operation was performed. After the patient＇s condition was stable, she was given oxaliplatin and capeeitabine to continue treatment.

关 键 词：贝伐珠单抗 肠穿孔 

分 类 号：R979.1[医药卫生—药品]